Introduction
============

Many forms of retinal degeneration result from genetic mutations, including Leber's congenital amaurosis (LCA), retinitis pigmentosa (RP), Stargardt disease, and cone--rod dystrophy (CORD). Many different genes have been discovered that, when mutated, lead to retinal degeneration. For LCA alone, mutations in 18 different genes have been discovered to be pathogenic, with about 30% of cases having no known genetic cause.[@b1-opth-12-049],[@b2-opth-12-049] RP can be caused by mutations in any one of over 80 different genes with many cases still having an unknown cause.[@b3-opth-12-049]--[@b5-opth-12-049] While there has been great progress in identifying disease-causing mutations for retinal degenerative diseases, this presents a staggering problem to the clinician: what is the most efficient and cost-effective test for identifying the genetic diagnosis?

Discovering genes that cause retinal degeneration when mutated and the specific mutations that do or do not cause disease is important to advancing the field. If the pathogenic mutation(s) can be identified in every patient with retinal degeneration, we will know how prevalent those mutations are, will be able to provide accurate prognoses, and will be better able to define potential patient populations for clinical trials. With the growing potential of novel strategies using gene editing (such as use of Clustered Regulatory Interspaced Short Palindromic Repeats) to correct specific genetic mutations, identifying not only the gene but also the specific mutations in each patient is becoming even more important. Identifying the pathogenic variants in retinal degeneration benefits basic science as well as clinical research. By identifying the genes that result in retinal degeneration when mutated, we gain a better understanding of how the retina works, which proteins are necessary for the various cellular processes that take place in the retina, and how they interact. By defining the specific mutations that are pathogenic (and which ones are tolerated), we better understand the function of these proteins and domains. This information can also be used to develop gene-based treatments (ie, gene therapy).

The present report reviews our own experience in seeking genetic diagnoses for retinal degeneration patients seen over a 5-year period at ophthalmology clinics at the Perelman School of Medicine, University of Pennsylvania and The Children's Hospital of Philadelphia as well as other patients who self-referred and agreed to participate in our molecular genetic research study. We carried out preliminary screens of these individuals in an attempt to identify known disease-causing variants. We followed up with whole exome sequencing (WES). Finally, we assessed the efficiency of making the correct genetic diagnosis using these techniques.

Subjects and methods
====================

Recruitment
-----------

Individuals seen in the Scheie Eye Institute and The Children's Hospital of Philadelphia retina clinics who were found to have a degenerative condition (and first-degree relatives) were invited to submit a blood sample for molecular genetics research testing. Study procedures were approved by the University of Pennsylvania Institutional Review Board (\#808828) and each individual provided signed informed consent. Parental or guardian permission and signed informed consent as well as signed assent were obtained for subjects younger than 18 years.

Whole exome sequencing
----------------------

Purified, target-enriched genomic samples from 69 patients with various form of retinal degeneration (including LCA, RP, Stargardt disease, CORD, and achromatopsia) to the Penn Genome Frontiers Institute were evaluated by WES ([Table 1](#t1-opth-12-049){ref-type="table"}). Samples had previously been screened using Asper Ophthalmics (Tartu, Estonia) arrayed primer extension (APEX) multigene panels for the relevant disease (using panels that were available from 2009 to 2014) and no disease-causing variants had been identified. Target enrichment was performed with the Agilent SureSelect target enrichment system (Agilent Technologies, Santa Clara, CA, USA), and the sequencing was performed on Illumina HiSeq2000 (Illumina, San Diego, CA, USA).

Mapping and variant identification
----------------------------------

Mapping and variant identification was performed using Galaxy.[@b6-opth-12-049] The FASTQ files for each patient were mapped to the reference human genome (hg18) using Burrows-Wheeler Aligner for Ilumina. Variants were identified using freebayes.[@b7-opth-12-049] Variants were annotated using Annovar.[@b8-opth-12-049]

Identifying variants of interest
--------------------------------

A semi-masked analysis was used to identify potentially pathogenic mutations without knowledge of the type of retinal degeneration. We created a curated list of genes linked to any form of retinal degeneration and used a python script (Python Software Foundation, Fredericksburg, VA, USA) to create a customized list of potential pathogenic variants for each patient. This list consisted of retinal degeneration genes with variants with an allele frequency of ,0.05. Those mutations were then prioritized based on mutation type and known facts about the mutations from the Single Nucleotide Polymorphism Database (dbSNP) (<https://www.ncbi.nlm.nih.gov/projects/SNP/>) and the Universal Protein Resource (UniProt; <http://www.uniprot.org>), which are known to be benign, pathogenic, novel variant, etc. We then checked if the variants were consistent with the clinical diagnosis and performed segregation analysis when possible.

We verified the possible pathogenic mutations in the patients and relatives by polymerase chain reaction, Phusion polymerase (New England Biolabs, Ipswich, MA, USA) and custom primers made by Thermo Fisher Scientific (Waltham, MA, USA) followed by Sanger sequencing by the Penn Genomics Analysis Core. The sequences were visualized using SnapGene software (from GSL Biotech, Chicago, IL, USA; available at [snapgene.com](https://snapgene.com)).

Results
=======

Prior to embarking on WES studies, APEX screening was carried out on 100 unrelated subjects, screening for *ABCA4* variants in individuals diagnosed with Stargardt disease, CORD, and macular degeneration, for variants in a panel of genes known to cause LCA for those diagnosed with LCA, achromatopsia, or nanophthalmos, and for genes associated with autosomal recessive or autosomal dominant RP (ADRP) in those diagnosed with RP, Usher Syndrome, vitreoschisis, or unspecified retinal degeneration ([Table 1](#t1-opth-12-049){ref-type="table"}).

Compound heterozygous or homozygous disease-causing variants were identified through APEX screening in 44% of those screened for *ABCA4* variants and 31% screened for LCA variants. Heterozygous or compound heterozygous disease-causing variants were identified in \~29% of those screened for RP variants. These disease-causing variants were confirmed by segregation studies in cases where informative family members were available. This left us with 69 individuals in whom either no disease-causing variants or only one potential disease-causing variant (in cases of autosomal recessive RP) had been identified. We identified the pathogenic mutations in 44 of those 69 subjects (64%) using WES. Sixty-six different mutations were found in 26 different genes. Eighteen of these mutations are completely novel and not listed in dbSNP. Eleven more are extremely rare, have no prediction on pathogenicity, and are not in any published study (see Supplementary materials for specific mutations in each form of retinal degeneration).

De novo mutations
-----------------

De novo mutations pose a particular problem when trying to identify pathogenic mutations. Dominant de novo mutations appear to be recessive when looking at the family history. We found two de novo mutations in our patient cohort. The first was a heterozygous novel frameshift mutation in *OTX2*, a known mutational hotspot, in a patient with LCA ([Table 2](#t2-opth-12-049){ref-type="table"}; JB275). *OTX2* is a transcription factor that is essential for development of the brain and retina. All known mutations are autosomal dominant. Knockout of *OTX2* is embryonic lethal in mice due to the absence of the forebrain and midbrain.[@b9-opth-12-049] *OTX2* is essential for photoreceptor differentiation as well as pituitary development. Knockout of *OTX2* in mouse retinal cells results in a failure to develop photoreceptors.[@b10-opth-12-049] *OTX2* mutations can result in syndromic microphthalmia, combined pituitary hormone deficiency, and early-onset retinal dystrophy with or without pituitary dysfunction.[@b11-opth-12-049]--[@b13-opth-12-049] The frameshift mutation was not present in either parent.

Another subject presented with cone dystrophy beginning at age 15. Neither parent had any form of retinal degeneration, so it was presumed that the genetic cause was recessive. Upon analysis of the WES dataset, we found that the proband was heterozygous for a p.Y99C mutation in *GUCA1A* ([Table 2](#t2-opth-12-049){ref-type="table"}; JB185), a well-characterized dominant mutation leading to cone dystrophy.[@b14-opth-12-049],[@b15-opth-12-049] Neither parent carried the p.Y99C mutation. Paternity was confirmed using the WES results of the parents and proband, indicating that the p.Y99C mutation was a de novo mutation.

Identification of *KIF7* as a candidate gene for cone dystrophy
---------------------------------------------------------------

A 5-year-old boy with cone dystrophy was found to have a compound heterozygous mutation in *KIF7* (p.H1115Q and p.Q834R; [Table 2](#t2-opth-12-049){ref-type="table"}; JB307). *KIF7* is a cilia gene that plays an important role in hedgehog signaling and microtubule stability.[@b16-opth-12-049],[@b17-opth-12-049] KIF7 localizes to the primary cilia, specifically the distal tip.[@b18-opth-12-049] Mutations in *KIF7* cause the cilia to become longer than normal and disorganized.[@b18-opth-12-049] Knockout of *Kif7* in mice is neonatal lethal.[@b17-opth-12-049] Mutations in *KIF7* have been shown to cause severe ciliopathies including Joubert syndrome, hydrolethalus syndrome, acrocallosal syndrome, Meckel--Gruber syndrome, and Bardet--Biedl syndrome (BBS).[@b19-opth-12-049] Both variants in the patient in this study have been previously identified as hypomorphic variants and have been seen in patients with BBS, Meckel--Gruber syndrome, and hydrolethalus syndrome.[@b20-opth-12-049] Typically, when a missense mutation in *KIF7* leads to disease, the other allele is a null allele with either a truncation or frameshift mutation.[@b20-opth-12-049],[@b21-opth-12-049] In this case, both alleles are rare hypomorphic variants (allele frequency in 1,000 genomes are 0.0010 and 0.0058 for p.Q834R and p.H1115Q, respectively). In addition to the compound heterozygous mutations, the subject was heterozygous for mutations in several other cilia genes, including a pathogenic mutation in *BBS1*. Ciliopathies have been shown to have a range of severities depending on the mutation in the gene.[@b38-opth-12-049] For example, *CEP290* mutations can result in retinal degeneration alone (specifically LCA), syndromic ciliopathies (Joubert syndrome or Meckel syndrome), and neonatal lethal ciliopathies.[@b38-opth-12-049]--[@b41-opth-12-049] This range appears to be due to the amount of functional CEP290 that remains.[@b22-opth-12-049] *KIF7* could be similar to *CEP290* in that severe mutations like truncations and frameshifts result in more severe ciliopathies, while compound heterozygosity of hypomorphic variants may result in only retinal degeneration. It is unknown why the cone photoreceptors would be affected while the rod photoreceptors are currently preserved.

Additional mutations
--------------------

Some of the patients had potentially pathogenic mutations in additional genes linked to retinal degeneration. Most of these additional mutations were heterozygous and, therefore, unlikely to be the disease-causing mutation in the patient. However, it is possible that the heterozygous mutations, which can be tolerated in isolation, add to the mutational load and modify the patient's phenotype.[@b23-opth-12-049] Five subjects had an unusually high number of additional mutations ([Tables 3](#t3-opth-12-049){ref-type="table"} and [4](#t4-opth-12-049){ref-type="table"}). Some of the mutations are in genes that interact or are in the same pathway, increasing the chances of epistatic effect. It is important to note there is a high likelihood that these are incidental findings that do not contribute to disease phenotype at all. One of the drawbacks of WES is that rare but benign variants are found and can complicate analyses.

No disease-causing variants identified
--------------------------------------

We were unable to conclusively determine the disease-causing variants in 20 subjects in the study. Five of these had a presumably recessive disease with one pathogenic or likely pathogenic variant identified that is consistent with their disease phenotype ([Table 5](#t5-opth-12-049){ref-type="table"}). These patients should be screened for copy number variants in the gene identified or possibly for intronic variants. Of the remaining 20 subjects, 9 do not have family members willing to enroll in the study. Since we did not find any obviously pathogenic variants in the initial screening and are unable to perform segregation analysis for the variants identified, we are unable to determine the pathogenicity of the variants identified. One of these subjects has many known pathogenic, likely pathogenic, and novel variants, but all are inconsistent with the diagnosis of ADRP[@b46-opth-12-049]--[@b48-opth-12-049] and we are unable to perform segregation analysis to narrow down the disease-causing variant(s) ([Table 4](#t4-opth-12-049){ref-type="table"}). The remaining 10 subjects should be analyzed for novel genes that could cause retinal degeneration ([Figure 1](#f1-opth-12-049){ref-type="fig"}).

Discussion
==========

WES is a powerful tool to help identify new mutations in patients who test negative for the known pathogenic mutations for retinal degeneration. However, the majority of mutations in these patients are in genes already linked to retinal degeneration. Forty-four of the 69 probands in our study, all of whom had had negative screenings using gene panels for their disease, were found to harbor pathogenic mutations in genes already linked to retinal degeneration. Thus, we found that if we failed to find the pathogenic mutation in a patient with retinal degeneration using standard APEX microarrays for their disease, it could be more time- and cost-efficient to use targeted sequencing of all genes linked to retinal degeneration rather than WES. Use of a targeted sequencing approach would also allow good coverage of the area of interest without the expense of deeper coverage of the whole exome. When we restricted our analysis of the WES data to genes linked to retinal degeneration, it allowed us to find novel mutations in those genes as well as mutations that are known to cause a different form of retinal degeneration.

WES is a powerful tool for identifying pathogenic mutations in genes by quickly identifying all variants in a patient's exome. It sequences the entire protein coding portion of the genome, which is about 2% of the total genome. Since the noncoding portion is not sequenced, it is cheaper than whole genome sequencing (WGS) and allows for greater depth of coverage. The large majority of disease-causing variants are in the exome, so although intronic mutations are missed, it is still usually more cost-effective to use WES and follow-up with WGS or targeted sequencing if WES fails to identify the cause of disease.

Although the size of the dataset generated by WES is smaller than WGS, sorting through the large amount of data generated to find the relevant variants is still a challenge. Filtering the dataset based on inheritance pattern, disease phenotype, and other predetermined criteria can not only make the dataset more manageable, but also risks filtering out pathogenic variants. De novo mutations can result in a dominant mutation in a patient whose disease is presumed to be recessive. Dominant mutations can also be revealed by findings of non-paternity (and concomitant incorrect family history). Diagnosis is based on qualitative assessment and psychophysical testing, and many forms of retinal degeneration have significant phenotypic overlap with each other. A patient can be diagnosed with a nonsyndromic form of retinal degeneration when they have a syndromic form if they have not yet developed extraocular symptoms. In these cases, it is easy to filter out pathogenic variants if the filters are too strict.

Limiting our initial screening to the genes that are known to cause one particular form of retinal degeneration after the subject has already come back negative from the typical first-pass screening (such as APEX array or single nucleotide polymorphism chip) would have been unnecessarily restrictive. It would have placed too much confidence in the accuracy of the clinical diagnosis when there is significant overlap between different forms of inherited retinal degeneration, especially given the fact that the subjects are known to be negative for the typical disease-causing mutations associated with that diagnosis. Further, at both early and late stages of retinal degeneration, it may be difficult to distinguish one form of disease from another. The possibility of de novo mutations and inaccurate family history makes it impossible to determine the inheritance pattern with complete certainty even in the best case scenario. There are also multiple genes that are linked to multiple forms of retinal degeneration, with the mechanism by which they can differentially affect rods and cones still not understood. It is entirely possible that a gene in which mutations are known to cause only RP or LCA currently could in fact also have mutations that lead to cone dystrophy. When one adds in the possibility of digenic cause and epistatic effects, it becomes even clearer that limiting analysis by the form of retinal degeneration is overly simplistic and can lead to missed pathogenic mutations.

Using a broader filter (retinal degeneration in general instead of the specific diagnosis) does come with an increased analytical burdened with more variants to sort through and can run the risk of becoming distracted by irrelevant variants. A mutation in rhodopsin is unlikely to cause cone dystrophy, but irrelevant variants can be quickly filtered out by a knowledgeable analyst and mutations in more relevant genes are prioritized. Since the list of genes to be screened is still specialized, our knowledge of the genes and the diseases that they are usually associated with can be used to prioritize the list of candidate genes. This would not be the case if the list used consisted of simply genes expressed in the retina where there are many genes whose function is unknown and, thus, with unknown disease involvement.

So far, most of the mutations we have found that lead to retinal degeneration follow typical Mendelian genetics. However, many patients with retinal degeneration do not have a known cause. It is probable that at least some of these cases will be found to be due to the additive or epistatic effects of mutations in more than one gene. Especially in the case of a presumed recessive inheritance pattern, the possibility that the cause is polygenic rather than monogenic cannot be discounted. In light of that possibility, screening all genes with mutations known to cause or contribute to retinal degeneration is important. The fact that these genes code for proteins vital to the proper functioning of the retina has already been established. A mutation or variant in a gene that reduces the ability to function (but not so much that it is sufficient to cause disease in the general population) might very well add to the mutational load that predisposes someone to retinal degeneration.

By using a semi-masked analysis in our screening, we were able to easily identify two patients with dominant de novo mutations as well as several with an inaccurate or incomplete incoming diagnosis. Many of the subjects in our study self-reported the initial diagnosis, which decreases the initial accuracy. However, there is some inherent unreliability in the initial diagnosis for early-stage retinal degeneration, particularly if this is made by a nonspecialist. Some forms of retinal degeneration, like RP, could be a part of a syndromic form of retinal degeneration like BBS. By not taking into account the type of retinal degeneration until after the possible mutations have been identified, we eliminate the possibility of filtering out obviously pathogenic variants before we even begin the analysis. Elicitation of a detailed family and clinical history as well as a focused clinical examination would significantly narrow down the search for the disease-causing gene during first-pass screening and is also likely most economical in avoiding the cost and time associated with WES and subsequent bioinformatics analyses (Stone et al,[@b25-opth-12-049] who demonstrated in a study of 1,000 different families that the disease-causing gene/variant could be identified in 57.6% of families without using WES). Identifying the disease-causing gene during first-pass screening would also eliminate the possibility of evaluating irrelevant seemingly pathogenic variations (such as those identified in families evaluated by Stone et al[@b25-opth-12-049]).

One cautionary finding from our study is that there were several patients who had areas of low coverage in genes of interest. One patient with Stargardt disease had a gap in coverage in *ABCA4* that masked the pathogenic mutation. Such gaps need to be filled in with Sanger sequencing. A gap in coverage can complicate analysis if not detected as it would essentially show no mutation in the area with no or low coverage.

We believe that all subjects should undergo appropriate psychophysical testing in order to refine the clinical diagnosis and then undergo a panel mutation screening for that diagnosis before being enrolled in a study for novel gene detection. This should be followed by targeted exome sequencing of all genes linked to retinal degeneration. In our study, 64% of the subjects were eliminated from further analysis after screening only genes linked to retinal degeneration. Subjects with a recessive disease in which only one pathogenic mutation is found (7% of the patients in this study, 20% of those without a genetic diagnosis) should be screened for copy number variants and intronic variants in that gene. After eliminating those enrolled in the study with no relatives, this would leave only 16% for a more in-depth analysis using WES.

The subjects with an unusually high mutational load merit further study as well. We tend to view sporadic cases of early-onset retinal degeneration as being due to an autosomal recessive mode of inheritance, or occasionally a de novo mutation. Modifying alleles are sometimes identified which increase the severity of the disease phenotype, like the p.A229T variant in *RPGRIP1L*.[@b24-opth-12-049] However, the consequence of multiple heterozygous variants that can be pathogenic if there is a second mutation in the same gene has not been studied. Screening the unaffected relatives of the three subjects with an unusually high mutational load could help illuminate how many mutations can be tolerated. Studying the progression of retinal degeneration in these subjects can help show whether the additional mutations result in a more severe phenotype or have no obvious effect.

Conclusion
==========

WES is a very effective approach for identifying novel mutations and narrowing down candidate genes for further analysis, especially when paired with targeted analysis based on known retinal pathways. If WES does not yield a molecular genetic diagnosis or a likely candidate for further analysis, WGS can be used to identify noncoding (intronic) mutations. While analysis of the parents and immediate family of the proband is not always required for identification of pathogenic variants, it does increase the likelihood of identifying pathogenic variants and could be needed if the mutations are not obviously pathogenic.

Supplementary materials
=======================

Syndromic disease
-----------------

Three siblings in one family were diagnosed with retinitis pigmentosa (RP). Whole exome sequencing (WES) revealed two variants in *BBS4* in the proband ([Table 2](#t2-opth-12-049){ref-type="table"}; JB319). The first mutation was a frameshift mutation likely resulting in nonsense mediated decay. The second mutation was p.R295G. While the arginine to glycine mutation is novel, an arginine to proline mutation at the same location has been previously reported to be pathogenic, making it very likely that the glycine substitution would be pathogenic as well.[@b99-opth-12-049] Mutations in *BBS4* have been shown to cause Bardet--Biedl syndrome (BBS), but not nonsyndromic RP. Segregation analysis confirmed that all three siblings were compound heterozygous for the *BBS4* mutations and clinical analysis showed that their symptoms (RP, obesity, and learning difficulties) were consistent with mild BBS. Renal dysfunction, polydactyly, and male hypogonadism are also commonly seen in BBS, but were absent in this family.[@b100-opth-12-049]

Another subject had Usher syndrome, a condition characterized by hearing loss and RP. Clinical testing failed to reveal any known mutations leading to Usher syndrome. WES revealed two novel frameshift mutations in *GPR98* ([Table 2](#t2-opth-12-049){ref-type="table"}; JB324), a gene known to cause Usher syndrome when mutated.[@b101-opth-12-049] Another subject with Usher syndrome was found to have two mutations in *USH2A* ([Table 2](#t2-opth-12-049){ref-type="table"}, JB252) that had been already classified as pathogenic.

Stargardt, cone dystrophy, and achromatopsia
--------------------------------------------

Stargardt disease is a childhood-onset macular degeneration and is most commonly caused by mutations in *ABCA4*. Characteristic yellow flecks are typically seen under the macula during a fundus exam. Five subjects presented with Stargardt disease and were found to have mutations in *ABCA4* ([Table 2](#t2-opth-12-049){ref-type="table"}; JB260, JB333, JB358, JB16, JB320). Six of the mutations had been previously characterized and determined to be pathogenic, while three novel frameshift mutations were found.

Autosomal dominant Stargardt disease is caused by mutations in *PROM1*. Interestingly, the dominant mutations seem to cause primarily cone degeneration, while the recessive mutations can cause either rod or cone degeneration. The dominant mutations in *PROM1* are typically gain-of-function missense mutations, while the recessive mutations are loss-of-function mutations including frameshift mutations, splice site mutations, and truncations. Two loss-of-function variants were identified in patients with either Stargardt disease or cone dystrophy ([Table 5](#t5-opth-12-049){ref-type="table"}; JB189, JB241). A second variant was not identified in either case. Since a dominant inheritance pattern was not established in these families, the pathogenicity of these variants is currently undetermined.

One subject diagnosed with Stargardt disease was found to have a heterozygous p.V242M variant in *CRX* ([Table 3](#t3-opth-12-049){ref-type="table"}; JB195). This mutation is reported to be pathogenic and cause autosomal dominant cone--rod dystrophy.[@b102-opth-12-049] CRX is a transcription factor that is required for the development and maintenance of cone photoreceptors.[@b103-opth-12-049] While many *CRX* mutations have been shown to reduce the ability of CRX to activate the rhodopsin promoter in vitro, the p.V242M mutation did not appear to affect the ability of CRX to activate the rhodopsin promoter, casting some doubt on the pathogenicity.[@b104-opth-12-049] It is possible that the p.V242M variant is pathogenic but has a different functional effect. The variant did not segregate with disease in the family in this study. Both the mother and half-sister are heterozygous for the variant, but do not have retinal degeneration. It is possible that the p.V242M variant contributes to mutational load or digenic cause for disease, but based on the lack of segregation and lack of demonstrated functional effect, the variant is probably benign.

Another subject presented with severe retinal degeneration that was classified as either achromatopsia or Leber's congenital amaurosis (LCA; [Table 2](#t2-opth-12-049){ref-type="table"}; JB301). The proband had two novel mutations in *GNAT2*, a frameshift mutation and a missense mutation. *GNAT2* encodes the alpha subunit of cone transducing, which is essential for phototransduction in cones.[@b105-opth-12-049] Truncations are the most common pathogenic mutations in *GNAT2*, but pathogenic missense mutations in *GNAT2* have been seen in both patients and mice.[@b106-opth-12-049],[@b107-opth-12-049] Complicating the interpretation of the sequencing results for this subject, she had a p.A249E heterozygous mutation in *GDF6* that has been reported to be autosomal dominant with incomplete penetrance.[@b108-opth-12-049]--[@b109-opth-12-049] This variant has been reported to lead to LCA, microphthalmia, and Klippel--Feil syndrome. Notably, this subject does not have any skeletal defects that are sometimes reported to be associated with the p.A249E variant. The mother, who does not exhibit any symptoms of retinal degeneration, is positive for the missense variant in *GDF6*. Therefore, we determined that the *GNAT2* mutations are the most likely genetic cause in this subject, with the *GDF6* mutation potentially acting as a modifying allele and increasing the severity or playing no role in retinal degeneration in this subject.

Another subject had an incoming diagnosis of LCA that was changed to cone dystrophy upon examination. The diagnosis was further modified to achromatopsia after WES revealed two heterozygous mutations in *CNGB3*, one of which was novel ([Table 2](#t2-opth-12-049){ref-type="table"}; JB426).

Leber's congenital amaurosis
----------------------------

LCA is a severe retinal degeneration which is symptomatic before the first year of age.[@b110-opth-12-049] The retinal degeneration eventually includes cone loss as well. It is one of the most severe forms of hereditary blindness. In this study, we found mutations in five different genes that resulted in LCA ([Table 2](#t2-opth-12-049){ref-type="table"}). Nine of the mutations (in *ABCA4*, *CNGB3*, *KCNJ13*, and *PROM1*) were novel.

*CEP290* mutations are the most common cause of LCA. CEP290 is essential for cilia development and maintenance.[@b111-opth-12-049],[@b112-opth-12-049] Mutations in *CEP290* cause many different ciliopathies including Joubert syndrome, Bardet--Biedl syndrome, Meckel syndrome, and Senior--Loken syndrome.[@b113-opth-12-049],[@b114-opth-12-049] We found a novel splice site mutation in *CEP290* in one patient with LCA ([Table 2](#t2-opth-12-049){ref-type="table"}; JB165). The second mutation was the deep intronic splice mutation.[@b115-opth-12-049] This case illustrates one of the limitations of WES for finding pathogenic mutations. WES did not reveal the deep intronic mutation. Since the *CEP290* c.2991+1655A\>G mutation is the most common mutation leading to LCA, the patient had been screened for it previously. If the mutation had not already been identified and specifically looked for, we would not have identified the second mutation or been able to determine if the *CEP290* splice site mutation was actually disease causing in this case or if the patient was simply a carrier for the mutation.

Mutations in *PRPH2* tend to be autosomal dominant due to haploinsufficiency.[@b116-opth-12-049] Typically, these mutations cause either RP or macular degeneration.[@b117-opth-12-049],[@b118-opth-12-049] Homozygous or compound heterozygous mutations are much rarer and cause LCA or early-onset RP when they do occur.[@b119-opth-12-049] The parents do not always have any functional vision loss, but will usually show signs of mild retinal degeneration when examined. One subject in this study was homozygous for a novel truncating mutation in *PRPH2* ([Table 2](#t2-opth-12-049){ref-type="table"}; JB310).

One subject was initially diagnosed with LCA. WES revealed two mutations in *PDE6A* ([Table 1](#t1-opth-12-049){ref-type="table"}; JB28), which have been shown to result in RP. Upon re-evaluation, the diagnosis was changed to early-onset RP, which has a later age of onset and typically less severe progression.

Retinitis pigmentosa
--------------------

RP is a progressive form of retinal degeneration that primarily affects rod photoreceptors. It has a later onset than LCA with a typical age of diagnosis of 35 years. There is a wide range for the age of onset with some patients diagnosed during childhood and others being diagnosed in their 60s or even later.[@b120-opth-12-049],[@b121-opth-12-049] RP can be x-linked, autosomal dominant, or autosomal recessive. Over 80 genes have been identified that can cause RP, and the genetic cause is unknown in almost half of all patients diagnosed.[@b122-opth-12-049] In this study, 10 different genes were found to cause RP with two novel mutations ([Table 2](#t2-opth-12-049){ref-type="table"}). All of the genes have been previously shown to cause RP.

Autosomal dominant RP accounts for 15%--40% of all cases of RP.[@b123-opth-12-049],[@b124-opth-12-049] So far, more than 20 genes have been identified that cause autosomal dominant RP.[@b123-opth-12-049],[@b124-opth-12-049] These include *CA4*, *PRPH2*, and *PRPF31*. Dominant mutations tend to be pathogenic either due to heterozygous insufficiency or they cause a toxic gain of function. Mutations in all three of these genes seem to cause disease at least in part due to haploinsufficiency as a null allele is sufficient to cause disease. The novel mutation we found in *PRPH2* is an early stop codon, so we did not follow-up with functional testing. The mutations in *CA4* and *PRPF31* are missense mutations that are near-known pathogenic missense mutations in the genes. CA4 mutations have been shown to impair the ability of the cells to regulate intracellular pH.[@b125-opth-12-049] The p.Q254P mutation in *CA4* ([Table 2](#t2-opth-12-049){ref-type="table"}; JB42) is very rare and currently classified as a variant with uncertain significance on dbSNP (rs150432787). We were unable to perform a segregation analysis due to the lack of DNA from family members. Interestingly, this patient was heterozygous for several mutations that are known to cause recessive forms of retinal degeneration, including *USH2A*, *ABCA4*, and *CDH23*, as well as novel mutations in several other genes linked to retinal degeneration, including *BBS12*, *ROM1*, and *GPR98*. This is an unusually high mutational load ([Table 3](#t3-opth-12-049){ref-type="table"}).
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![Final outcome of initial screening for variants in genes associated with retinal degeneration.\
**Notes:** Of the initial cohort of 69 subjects with retinal degeneration, the pathogenic variants were identified in 44 subjects, heterozygous mutations consistent with the diagnosis were identified in 5 subjects, and 9 subjects had no obviously pathogenic variants and lacked relatives willing or able to enroll in the study to perform segregation analysis on potentially pathogenic variants. Eleven are good candidates for further analysis to find novel genes associated with retinal degeneration.](opth-12-049Fig1){#f1-opth-12-049}

###### 

Breakdown of diagnoses included in this study

  Incoming clinical diagnosis               Number of patients
  ----------------------------------------- --------------------
  autosomal dominant retinitis pigmentosa   5
  Cone dystrophy                            3
  Cone-rod dystrophy                        2
  Leber's congenital amaurosis              24
  Macular dystrophy                         1
  Nanophthalmos                             1
  Retinitis pigmentosa                      15
  Stargardt                                 11
  Usher syndrome                            2
  Achromatopsia                             1
  Vitreoschisis                             1
  Retinal degeneration (unspecified)        2

###### 

Pathogenic and probable pathogenic variants in known disease-causing genes identified in subjects in this study

  Subject                  Dx                                                    Gene          Nucleotide change                                                                Protein change           dbSNP         Reference
  ------------------------ ----------------------------------------------------- ------------- -------------------------------------------------------------------------------- ------------------------ ------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  JB260                    Stargardt                                             *ABCA4*       c.6119G\>A                                                                       p.Arg2040Gln             rs148460146   Zernant et al (2014)[@b50-opth-12-049]
  c.2879del                p.Ala960Aspfs\*17                                     N/A                                                                                                                                   
  JB333                    Stargardt                                             *ABCA4*       c.4363T\>C                                                                       p.Cys1455Arg             rs758835368   Fujinami et al (2013)[@b51-opth-12-049]
  c.4666del                p.Arg1556Glyfs\*25                                    N/A                                                                                                                                   
  JB358                    Stargardt                                             *ABCA4*       c.2588G\>C                                                                       p.Gly863Ala              rs76157638    Maugeri et al (2000)[@b52-opth-12-049]
  c.3984_3987del           p.His1328Glnfs^\*^60                                  N/A                                                                                                                                   
  JB16                     Stargardt                                             *ABCA4*       c.5917del                                                                        p.Val1973^\*^            rs61751389    Kitiratschky et al (2008)[@b53-opth-12-049]
  c.5917del                p.Val1973^\*^                                         rs61751389    Kitiratschky et al (2008)[@b53-opth-12-049]                                                                             
  JB320                    Stargardt                                             *ABCA4*       c.1749G\>C                                                                       p.Lys583Asn              rs145265791   Fujinami et al (2013)[@b51-opth-12-049]
  c.4594G\>A               p.Asp1532Asn                                          rs62642574    Briggs et al (2001)[@b54-opth-12-049]                                                                                   
  JB249                    LCA                                                   *AIPL1*       c.834G\>A                                                                        p.Trp278^\*^             rs62637014    Sohocki et al (2000)[@b55-opth-12-049]
  c.404_405insA            p.Glu135fs^\*^23                                      N/A                                                                                                                                   
  JB319                    RP (BBS)                                              *BBS4*        c.513_514insA                                                                    p.Ile172Asnfs\*18        rs779047261   Mykytyn et al (2001)[@b26-opth-12-049]
  c.883C\>G                p.Arg295Gly                                           N/A           Priya et al (2016)[@b27-opth-12-049]                                                                                    
  JB42                     ADRP                                                  *CA4*         c.761A\>C                                                                        p.Gln254Pro              rs150432787   Yang et al (2005)[@b49-opth-12-049]
  JB165                    LCA                                                   *CEP290*      c.2991+1655A\>G                                                                  Splice mutation          rs281865192   den Hollander et al (2006)[@b41-opth-12-049]
  c.3461+2TA\>GT           Splice mutation                                       N/A                                                                                                                                   
  JB290                    LCA                                                   *CEP290*      c.2390del                                                                        p.Lys797Serfs^\*^2       rs781670422   Cideciyan et al (2011)[@b56-opth-12-049]
  c.2390del                p.Lys797Serfs^\*^2                                    rs781670422   Cideciyan et al (2011)[@b56-opth-12-049]                                                                                
  JB9                      Retinal degeneration (Batten disease)                 *CLN3*        c.597C\>A                                                                        p.Tyr199^\*^             rs267606737   Sarpong et al (2009)[@b57-opth-12-049]
  c.597C\>A                p.Tyr199^\*^                                          rs267606737   Sarpong et al (2009)[@b57-opth-12-049]                                                                                  
  JB255                    LCA (Batten disease)                                  *CLN3*        c.883G\>A CNV suspected\~                                                        p.Glu295Lys              rs121434286   Munroe et al (1997)[@b58-opth-12-049]
  JB426                    CORD (achromatopsia)                                  *CNGB3*       c.1148del                                                                        p.Thr383Ilefs^\*^13      rs397515360   Kohl et al (2005)[@b59-opth-12-049]
  c.1306A\>C               p.Ser436Arg                                           rs748354081                                                                                                                           
  JB274                    LCA                                                   *CRB1*        c.2300T\>C                                                                       p.Leu767Pro              N/A           
  c.2300T\>C               p.Leu767Pro                                           N/A                                                                                                                                   
  JB375                    RP                                                    *CRB1*        c.1576C\>T                                                                       p.Arg526^\*^             rs114342808   Seong et al (2008)[@b60-opth-12-049]
  c.1429G\>A               p.Gly477Arg                                           rs866822473   Abu-Safieh et al (2013)[@b61-opth-12-049]                                                                               
  JB402                    LCA                                                   *CRB1*        c.2843G\>A                                                                       p.Cys948Tyr              rs62645748    den Hollander et al (1999)[@b62-opth-12-049]
  c.3988G\>T               p.Glu1330^\*^                                         N/A                                                                                                                                   
  JB38                     RP                                                    *FAM161A*     c.1355_1356del                                                                   p.Thr452Serfs\*3         rs397704718   Bandah-Rozenfeld et al (2010)[@b63-opth-12-049]
  c.1355_1356del           p.Thr452Serfs                                         rs397704718   Bandah-Rozenfeld et al (2010)[@b63-opth-12-049]                                                                         
  JB301                    Achromatopsia                                         *GNAT2*       c.896C\>A                                                                        p.Ala299Glu              N/A           Nishiguchi et al (2005),[@b32-opth-12-049] Jobling et al (2013),[@b33-opth-12-049] and Kuniyoshi et al (2016)[@b34-opth-12-049]
  c.720+2T\>C              Splice mutation                                       N/A                                                                                                                                   
  JB324                    Usher                                                 *GPR98*       c.14767del                                                                       p.Thr4923Profs^\*^8      rs747459491   Weston et al (2004)[@b28-opth-12-049]
  c.17668_17669del         p.Met5890Valfs^\*^10                                  rs757696771                                                                                                                           
  JB185                    Cone dystrophy (ad)                                   *GUCA1A*      c.296A\>G                                                                        p.Tyr99Cys               rs104893967   Payne et al (1998)[@b14-opth-12-049]
  JB282                    LCA                                                   *GUCY2D*      c.2080C\>T                                                                       p.Gln694^\*^             rs61750164    Eisenberger et al (2013)[@b64-opth-12-049]
  c.1009_1010insCAGCAGCT   p.Asp337Alafs^\*^61 (p.Pro335_Ser336 insSer in cis)                                                                                                                                         
  JB307                    Cone dystrophy                                        *KIF7*        c.A2501A\>G                                                                      p.Gln834Arg              rs138354681   Putoux et al (2011)[@b20-opth-12-049]
  c.3345C\>G               p.His1115Gln                                          rs142032413   Putoux et al (2011)[@b20-opth-12-049]                                                                                   
  JB32                     RP                                                    *NR2E3*       c.119-2A\>C                                                                      Splice mutation          rs2723341     Bandah et al (2009)[@b65-opth-12-049]
  c.932G\>A                p.Arg311Gln                                           rs28937873    Haider et al (2000)[@b66-opth-12-049]                                                                                   
  JB181                    Nanophthalmos, maculopathy                            *NR2E3*       c.767C\>A                                                                        p.Ala256Glu              rs377257254   Sharon et al (2003)[@b67-opth-12-049]
  c.119-2A\>C              Splice mutation                                       rs2723341     Bandah et al (2009)[@b65-opth-12-049]                                                                                   
  JB48                     RP (ad)                                               *NR2E3*       c.166G\>A                                                                        p.Gly56Arg               rs121912631   Coppieters et al (2007)[@b68-opth-12-049]
  JB275                    LCA (ad retinal degeneration)                         *OTX2*        c.527del                                                                         p.Pro177^\*^             N/A           
  JB28                     LCA (EORD)                                            *PDE6A*       c.1705C\>A                                                                       p.Gln569Lys              rs139444207   Dryja et al (1999)[@b69-opth-12-049]
  c.1620+2T\>A             Splice mutation                                                                                                                                                                             
  JB33                     ADRP                                                  *PRPF31*      c.590T\>C                                                                        p.Leu197Pro              N/A           
  JB310                    LCA                                                   *PRPH2*       c.522G\>A                                                                        p.Trp174^\*^             N/A           
  c.522G\>A                p.Trp174^\*^                                          N/A                                                                                                                                   
  JB167                    AD retinal degeneration                               *PRPH2*       c.136C\>T                                                                        p.Arg46^\*^              rs61755771    
  JB46                     CORD                                                  *PRPH2*       c.514C\>T                                                                        p.Arg172Trp              rs61755792    Conley et al (2014),[@b42-opth-12-049] Meins et al (1993),[@b43-opth-12-049] Wroblewski et al (1994),[@b44-opth-12-049] and Wang et al (2013)[@b45-opth-12-049]
  JB284                    LCA                                                   *PROM1*       c.2050C\>T                                                                       p.R684^\*^               rs530749007   
  c.2050C\>T               p.R684^\*^                                            rs530749007                                                                                                                           
  JB44                     ADRP                                                  *RP1*         c.2029C\>T                                                                       p.Arg677^\*^             rs104894082   Payne et al (2000)[@b70-opth-12-049]
  JB372                    RP                                                    *RP1L1*       c.1138G\>A                                                                       p.Gly380Arg              rs184332984   Tiwari et al (2016) (for macular dystrophy)[@b71-opth-12-049]
  c.1138G\>A               p.Gly380Arg                                           rs184332984   Tiwari et al (2016) (for macular dystrophy)[@b71-opth-12-049]                                                           
  JB47                     RP                                                    *RP1L1*       c.1270A\>T                                                                       p.Lys424^\*^             rs770463388   
  c.1270A\>T               p.Lys424^\*^                                          rs770463388                                                                                                                           
  JB283                    LCA                                                   *RPE65*       c.1067_1068insA                                                                  p.Asn356Lysfs\*9         rs766074572   
  c.1067_1068insA          p.Asn356Lysfs\*9                                      rs766074572                                                                                                                           
  JB357                    LCA                                                   *RPE65*       c.1249G\>C                                                                       p.Glu417Gln              rs62636299    Simovich et al (2001)[@b72-opth-12-049]
  c.1102T\>C               p.Tyr368His                                           rs62653011    Yzer et al (2003)[@b73-opth-12-049]                                                                                     
  JB285                    LCA                                                   *RPGRIP1*     c.767C\>G                                                                        p.Ser256^\*^             N/A           
  c.1084_1087del           p.Arg363Leufs^\*^11                                   N/A                                                                                                                                   
  JB124                    LCA                                                   *RPGRIP1*     c.1180C\>T                                                                       p.Gln394^\*^             N/A           
  c.1180C\>T               p.Gln394^\*^                                          N/A                                                                                                                                   
  JB43                     RP                                                    *RPGRIP1L*    c.171G\>T                                                                        p.Leu57Phe               rs146925098   
  c.628A\>G                p.Asn210Asp                                           rs146584570                                                                                                                           
  JB41                     RP                                                    *USH2A*       c.1036A\>C                                                                       p.Asn346His              rs369522997   Weston et al (2000)[@b74-opth-12-049]
  c.13335_13337del         p.Glu4445_Asn4446delinsAsp                            rs775556188                                                                                                                           
  JB49                     RP                                                    *USH2A*       c.13297G\>T                                                                      p.Val4433Leu (benign?)   rs111033381   Dreyer et al (2008)[@b75-opth-12-049]
  c.6713A\>C               p.Glu2238Ala                                          rs41277212    Aller et al (2006)[@b77-opth-12-049] and McGee et al (2010)[@b76-opth-12-049]                                           
  JB252                    Usher                                                 *USH2A*       c.13207_13208del                                                                 p.Gly4403Profs\*15       rs746447649   Le Quesne Stabej et al (2012)[@b78-opth-12-049]
  c.2299del                p.Glu767Serfs^\*^21                                   rs80338903    Eudy et al (1998),[@b79-opth-12-049] and Weston et al (2000)[@b74-opth-12-049]                                          

**Note:** Only variants that completely explain the disease phenotype have been included in this table.

**Abbreviations:** ADRP, autosomal dominant retinitis pigmentosa; BBS, Bardet--Biedl syndrome; CORD, cone--rod dystrophy; dbSNP, database of single nucleotide polymorphisms; Dx, diagnosis; EORD, early-onset retinal degeneration; LCA, Leber's congenital amaurosis; NA, not applicable; RP, retinitis pigmentosa.

###### 

Additional heterozygous variants of uncertain significance found in this study

  Subject       Dx                                      Disease-causing gene   Other genes                                                                     Nucleotide change                         Protein change      dbSNP         Reference
  ------------- --------------------------------------- ---------------------- ------------------------------------------------------------------------------- ----------------------------------------- ------------------- ------------- -------------------------------------------------------------------------------------------------------------------------
  JB333         Stargardt                               *ABCA4*                *IQCB1*                                                                         c.772delA                                 p.Arg258Aspfs\*4    N/A           
  JB320         Stargardt                               *ABCA4*                *RD3*                                                                           c.16T\>C                                  p.Trp6Arg           rs35649846    Friedman et al (2006)[@b80-opth-12-049]
  c.69G\>C      p.Glu23Asp                              rs34422496             Friedman et al (2006)[@b80-opth-12-049]                                                                                                                     
  JB9           Retinal degeneration (Batten disease)   *CLN3*                 *MKKS*                                                                          c.1015A\>G                                p.Ile339Val (hom)   rs137853909   Slavotinek et al (2002)[@b81-opth-12-049]
  JB375         RP                                      *CRB1*                 *AHI1*                                                                          c.653A\>G                                 p.Tyr218Cys         rs183936286   Srour et al (2012)[@b82-opth-12-049] and Huang et al (2015)[@b83-opth-12-049]
  c.3257A\>G    p.Glu1086Gly                            rs148000791            Kroes et al (2008)[@b84-opth-12-049] and Srour et al (2012)[@b82-opth-12-049]                                                                               
  JB38          RP                                      *FAM161A*              *RPGRIP1L*                                                                      c.685G\>A                                 p.Ala229Thr         rs61747071    Khanna et al (2009)[@b24-opth-12-049]
  JB301         LCA vs achromatopsia                    *GNAT2*                *GDF6*                                                                          c.746C\>A                                 p.Ala249Glu         rs121909352   Asai-Coakwell et al (2009)[@b35-opth-12-049] and (2013)[@b36-opth-12-049] and Tassabehji et al (2008)[@b37-opth-12-049]
  JB32          RP                                      *NR2E3*                *USH2A*                                                                         c.2137G\>C                                p.Gly713Arg         rs696723      Dreyer et al (2000)[@b85-opth-12-049]
  c.10246T\>G   p.Cys3416Gly                            rs527236140            Huang et al (2013)[@b86-opth-12-049]                                                                                                                        
  JB181         Nanophthalmos, maculopathy              *NR2E3*                *ABCA4*                                                                         c.2828G\>A                                p.Arg943Gln         rs61749446    Yatsenko et al (2001)[@b87-opth-12-049] and Briggs et al (2001)[@b54-opth-12-049]
  JB184         Nanophthalmos, maculopathy              *NR2E3*                *ABCA4*                                                                         c.2828G\>A                                p.Arg943Gln         rs61749446    Yatsenko et al (2001)[@b87-opth-12-049] and Briggs et al (2001)[@b54-opth-12-049]
  JB48          ADRP                                    *NR2E3*                *USH2A*                                                                         c.10246T\>G                               p.Cys3416Gly        rs527236140   Huang et al (2013)[@b86-opth-12-049]
  c.14419G\>A   p.Ala4807Thr                            rs534656527                                                                                                                                                                        
  JB275         LCA (ad retinal degeneration)           *OTX2*                 *RP1*                                                                           c.5673G\>T                                p.Leu1891Phe        rs139088785   
  JB28          LCA (EORD)                              *PDE6A*                *IQCB1*                                                                         c.962T\>A                                 p.Val321Glu         N/A           
  JB284         LCA                                     *RD3*                  *USH2A*                                                                         c.10451G\>A                               p.Arg3484Gln        rs771999994   McGee et al (2010)[@b76-opth-12-049]
  c.13709G\>A   p.Arg4570His                            rs730254               McGee et al (2010)[@b76-opth-12-049]                                                                                                                        
  JB41          RP                                      *USH2A*                *RP2*                                                                           c.844C\>T                                 p.Arg282Trp (hom)   rs1805147     Breuer et al (2002)[@b88-opth-12-049] and Sharon et al (2000)[@b89-opth-12-049]
  JB49          RP                                      *USH2A*                *RP1*                                                                           c.4875A\>G                                p.Ile1625Met        rs757644601   
  JB195         Stargardt                               Unknown                *CRX*                                                                           c.724G\>A                                 p.Val242Met         rs61748459    Swain et al (1997)[@b29-opth-12-049] and Chen et al (1997)[@b30-opth-12-049] and (2002)[@b31-opth-12-049]
  JB42          ADRP                                    *CA4*                  *ABCA4*                                                                         c.1140T\>A                                p.Asn380Lys         rs61748549    Riveiro-Alvarez et al (2009)[@b90-opth-12-049]
  *BBS12*       c.617T\>G                               p.Val206Gly            N/A                                                                                                                                                         
  *CDH23*       c.1096G\>A                              p.Ala366Thr            rs143282422                                                                     Ouyang et al (2005)[@b91-opth-12-049]                                       
  *GPR98*       c.6017G\>A                              p.Gly2006Asp           rs768201036                                                                                                                                                 
  *USH2A*       c.2276G\>T                              p.Cys759Phe            rs80338902                                                                      Dreyer et al (2000)[@b85-opth-12-049]                                       
  JB307         Cone dystrophy                          *KIF7*                 *BBS1*                                                                          c.1169T\>G                                p.Met390Arg         rs113624356   Mykytyn et al (2003)[@b92-opth-12-049]
  *CEP164*      c.4228C\>T                              p.Gln1410\*            rs147398904                                                                                                                                                 
  *RPGRIP1*     c.1639G\>T                              p.Ala547Ser            rs10151259                                                                      Roepman et al (2000)[@b93-opth-12-049]                                      
  *CLN3*        c.1189G\>A                              p.Ala397Thr            rs754468227                                                                                                                                                 
  *RP1l1*       c.6359A\>G                              p.Glu2120Gly           N/A                                                                                                                                                         
  JB284         LCA (RP)                                *PROM1*                *USH2A*                                                                         c.13709G\>A                               p.Arg4570His        rs730254      McGee et al (2010)[@b76-opth-12-049]
  *USH2A*       c.13297G\>T                             p.Val4433Leu           rs111033381                                                                     Dreyer et al (2008)[@b75-opth-12-049]                                       
  *USH2A*       c.10451G\>A                             p.Arg3484Gln           rs771999994                                                                                                                                                 
  *RP1*         c.5840T\>G                              p.Leu1947Trp           N/A                                                                                                                                                         
  *RPGRIP1*     c.3341A\>G                              p.Asp1114Gly           rs17103671                                                                      Gerber et al (2001)[@b94-opth-12-049]                                       
  *BBS1*        c.700G\>A                               p.Glu234Lys            rs35520756                                                                      Beales et al (2003)[@b95-opth-12-049]                                       
  *ABCA4*       c.3602G\>T                              p.Leu1201Arg           rs61750126                                                                      Briggs et al (2001)[@b54-opth-12-049]                                       
  *RD3*         c.69G\>C                                p.Glu23Asp             rs34422496                                                                      Friedman et al (2006)[@b80-opth-12-049]                                     
  *RD3*         c.16T\>C                                p.Trp6Arg              rs35649846                                                                      Friedman et al (2006)[@b80-opth-12-049]                                     
  *WFS1*        c.862G\>A                               p.Val288Met            rs71537685                                                                                                                                                  
  *WFS1*        c.1949A\>G                              p.Tyr650Cys            N/A                                                                                                                                                         
  *WFS1*        c.2008G\>A                              p.Gly670Ser            N/A                                                                                                                                                         
  JB274         LCA                                     *CRB1*                 *KIF7*                                                                          c.A2501A\>G                               p.Gln834Arg         rs138354681   Putoux et al (2011)[@b20-opth-12-049]
  *BBS1*        c.1396G\>A                              p.Ala466Thr            N/A                                                                                                                                                         
  *FAM161A*     c.1133T\>G                              p.Leu378Arg            rs187695569                                                                     Langmann et al (2010)[@b96-opth-12-049]                                     
  *MAK*         c.112A\>C                               p.Lys38Gln             N/A                                                                                                                                                         
  *RGS9*        c.1351C\>A                              p.Gln451Lys            N/A                                                                                                                                                         

**Note:** These variants are unlikely to be pathogenic in the subjects, but we were unable to exclude the possibility that they act as modifying alleles.

**Abbreviations:** ADRP, autosomal dominant retinitis pigmentosa; BBS, Bardet--Biedl syndrome; CORD, cone--rod dystrophy; dbSNP, database of single nucleotide polymorphisms; Dx, diagnosis; EORD, early-onset reitnal degeneration; LCA, Leber's congenital amaurosis; N/A, not applicable; RP, retinitis pigmentosa.

###### 

Multiple compound heterozygous mutations identified in a subject with multiplex RP

  Subject      Dx             Disease-causing gene   Other genes   Nucleotide change                            Protein change   dbSNP        Reference
  ------------ -------------- ---------------------- ------------- -------------------------------------------- ---------------- ------------ ---------------------------------------
  JB40         Multiplex RP   Unknown                *RPGRIP1L*    c.685G\>A                                    p.Ala229Thr      rs61747071   Khanna et al (2009)[@b24-opth-12-049]
  *RPGRIP1L*   c.2952G\>C     p.Gln984His            rs775144757                                                                              
  *RPGRIP1L*   c.196C\>A      p.Gln66Lys             rs751444506                                                                              
  *CDH23*      c.1096G\>A     p.Ala366Thr            rs143282422   Ouyang et al (2005)[@b91-opth-12-049]                                      
  *CDH23*      c.3293A\>G     p.Asn1098Ser           rs41281310    Oshima et al (2008)[@b97-opth-12-049]                                      
  *FAM161A*    c.977A\>C      p.Lys326Thr            rs745318331                                                                              
  *GUCY2D*     c.3247C\>A     p.Leu1083Met           N/A                                                                                      
  *USH2A*      c.6713A\>C     p.Glu2238Ala           rs41277212    Aller et al (2006)[@b77-opth-12-049]                                       
  *USH2A*      c.1434G\>C     p.Glu478Asp            rs35730265    Seyedahmadi et al (2004)[@b98-opth-12-049]                                 

**Notes:** This family appears to have an unusually high number of recessive mutations rather than the single dominant mutation that was expected based on the family history. We were unable to perform segregation analysis. The *CDH23* mutations and the RPGRIP1L mutations are the most likely to be pathogenic.

**Abbreviations:** dbSNP, database of single nucleotide polymorphisms; Dx, diagnosis; N/A, not applicable; RP, retinitis pigmentosa.

###### 

Heterozygous variants identified in subjects with recessive disease

  Subject   Dx               Gene       Nucleotide change   Protein change                          dbSNP                 Reference
  --------- ---------------- ---------- ------------------- --------------------------------------- --------------------- ---------------------------------------
  JB200     Stargardt        *ABCA4*    c.2828G\>A          p.Arg943Gln (probable polymorphism)     rs1801581             Briggs et al (2001)[@b54-opth-12-049]
  JB188     Stargardt        *CNGB3*    c.2139_2160del      p.Lys714_Gln720del (p.Lys804\*in cis)   (rs151039691in cis)   Kohl et al (2005)[@b59-opth-12-049]
  JB23      LCA              *KCNJ13*   c.458C\>T           p.Thr153Ile                             rs863224884           
  JB189     Stargardt        *PROM1*    c.303+1G\>A         Splice mutation                         rs777673930           
  JB241     Cone dystrophy   *PROM1*    c.1623_1624del      p.Y541fs                                N/A                   

**Notes:** The variant is most likely pathogenic and is consistent with the diagnosis, but we were unable to identify the second mutation. These subjects should be screened for copy number variants and intronic variants.

**Abbreviations:** dbSNP, database of single nucleotide polymorphisms; Dx, diagnosis; LCA, Leber's congenital amaurosis; N/A, not applicable.
